Project Objective: Clinical Trial, Phase 2
Alpha Stem Cell Clinic for the Development of Regenerative Therapies
The proposed alpha clinic will bring together an outstanding team of physician-scientists with substantial clinical trials experience including stem cell and other cellular treatments of blood diseases and others. This team will also draw on our unique regional competitive advantages derived from our history of extensive collaboration with investigators at many nearby first-class research institutions […]
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium
Two world renowned research universities with their regional partners will join forces to create the CIRM Alpha Stem Cell Clinic (ASCC) Consortium. We are uniquely qualified by our respective institutional knowledge and collective experience to establish best practices for the delivery of stem cell therapies and education as we combine: 1) world class state-of-the-art medical […]
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases.
As the largest provider of bone marrow cell transplants in California, and the second largest in the nation, our institution has great expertise and an excellent record of safety in the delivery of stem cell treatments. We now propose to create the Alpha Clinic for Cell Therapy and Innovation (ACT-I) in which new, state-of-the-art, stem […]
Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction
The proposed research will demonstrate both safety and efficacy of a heart-derived stem cell product in patients who have experienced a heart attack either recently or in the past by conducting a mid-stage clinical trial. A prior early-stage trial showed that the product can repair damaged portions of the heart after a heart attack in […]
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)
Therapeutic Candidate or Device Novel testing of a cell based therapy (Mesenchymal Stromal Cells) for respiratory failure from ARDS. Indication COVID-19 positive or negative ARDS patients Therapeutic Mechanism It will hopefully improve oxygenation in ARDS patients and potentially decrease mortality. Unmet Medical Need There is an unmet need for more effective treatments for ARDS both […]
Phase 2 Study of Hematopoietic Stem Cell Gene Transfer Inducing Fetal Hemoglobin in Sickle Cell Disease
Therapeutic Candidate or Device Autologous CD34+ cells transduced ex vivo with the BCH_BB694 LCR(-HS4) bGp D12shmiR lentiviral vector Indication Sickle cell disease with severe phenotype. Therapeutic Mechanism Silencing of beta-sickle globin and induction of anti-sickling fetal hemoglobin Unmet Medical Need Sickle cell is a severe disease with protean manifestations. The only curative therapy is an […]
A hub and spoke community model to equitably deliver regenerative medicine therapies to diverse populations across four California counties
Expand capacities to deliver novel cell and gene therapy treatments to diverse communities across four California Counties (REAL: ORange, RivErside, San BernArdino, and Los Angeles). We will conduct regenerative medicine trials, train a diverse workforce, and deliver novel network offerings. UCI ASCC REAL will accelerate the delivery of regenerative medicine to all Californians, emphasizing diversity, […]
Alpha Clinic Network Expansion for Cell and Gene Therapies
The CIRM Alpha Clinic will expand capacities and workforce expertise to accelerate development, clinical testing, and dissemination of novel cell and gene therapies for a broad range of conditions that impact Californians across the lifespan and from diverse backgrounds and underserved communities. In 2020, Californians voted to increase their investment in regenerative medicine to address […]
Expansion of the Alpha Stem Cell and Gene Therapy Clinic at UCLA
The ASCC provides infrastructure and operational support across the Network to drive novel stem cell therapies from bench to bedside. The ASCC will engage underserved communities in California to increase education and access to regenerative medicine trials and therapeutics. The ASCC will accelerate the clinical trial pipeline of novel regenerative medicine therapeutics and solidify California […]
UC San Diego Health CIRM Alpha Stem Cell Clinic
1. Strengthen and expand collaborations with ASCC Network partners with lead offerings 2. Improve access to clinical trials for diverse populations 3. Expand regenerative medicine clinical trial portfolio in major UCSD ASCC focus areas, including of cancer, metabolic disease, and neurological disease Innovative stem cell and gene therapy clinical trials can be implemented and accelerated […]